Predictors of Treatment with Osteoporosis Medications After Recent Fragility Fractures in a Multinational Cohort of Postmenopausal Women

• Autores: Susan L. Greenspan, Allison Wyman, Frederick H. Hooven, Silvano Adami, Stephen Gehlbach, Frederick A. Anderson, Steven Boone, Andrea Z. Lacroix, Robert Lindsay, J. Coen Netelenbos, Johannes Pfeilschifter, Stuart Silverman, Ethel S. Siris, Nelson B. Watts
• Localización: Journal of the American Geriatrics Society, ISSN 0002-8614, Vol. 60, Nº. 3, 2012, págs. 455-461
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objectives: To determine the proportion of untreated women who reported receiving treatment after incident fracture and to identify factors that predict treatment across an international spectrum of individuals.

    Design: Prospective observational study. Self-administered questionnaires were mailed at baseline and 1 year.

    Setting: Multinational cohort of noninstitutionalized women recruited from 723 primary physician practices in 10 countries.

    Participants: Sixty thousand three hundred ninety-three postmenopausal women aged 55 and older were recruited with a 2:1 oversampling of women aged 65 and older.

    Measurements: Data collected included participant demographics, medical history, fracture occurrence, medications, and risk factors for fracture. Anti-osteoporosis medications (AOMs) included estrogen, selective estrogen receptor modulators, bisphosphonates, calcitonin, parathyroid hormone, and strontium.

    Results: After the first year of follow-up, 1,075 women reported an incident fracture. Of these, 17% had started AOM, including 15% of those with a single fracture and 35% with multiple fractures. Predictors of treatment included baseline calcium use (P = .01), baseline diagnosis of osteoporosis (P < .001), and fracture type (P < .001). In multivariable analysis, women taking calcium supplements at baseline (odds ratio (OR) = 1.67) and with a baseline diagnosis of osteoporosis (OR = 2.55) were more likely to be taking AOM. Hip fracture (OR = 2.61), spine fracture (OR = 6.61), and multiple fractures (OR = 3.79) were associated with AOM treatment. Age, global region, and use of high-risk medications were not associated with treatment.

    Conclusion: More than 80% of older women with new fractures were not treated, despite the availability of AOM. Important factors associated with treatment in this international cohort included diagnosis of osteoporosis before the incident fracture, spine fracture, and to a lesser degree, hip fracture.